Medicine & Life Sciences
Prostatic Neoplasms
100%
T-Cell Antigen Receptor
45%
Peptides
44%
MDV 3100
41%
T-Lymphocytes
39%
Nivolumab
38%
DNA Mismatch Repair
36%
Prostate-Specific Antigen
34%
Castration
30%
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
27%
Androgens
26%
Turcot syndrome
25%
NAADP
23%
Androgen Receptors
22%
Antigens
21%
pembrolizumab
19%
Ipilimumab
19%
Deep Learning
19%
HLA-A2 Antigen
19%
Drug Approval
18%
Acute Promyelocytic Leukemia
17%
Mutation
16%
Carcinoma, Intraductal, Noninfiltrating
16%
Non-Randomized Controlled Trials
16%
Neoplasms
16%
Carcinoid Tumor
15%
Hormones
15%
Exocytosis
15%
Immunotherapy
15%
Major Histocompatibility Complex
14%
United States Food and Drug Administration
13%
Renal Cell Carcinoma
13%
Antibodies
12%
Cold Temperature
12%
Transgenic Mice
12%
Vaccines
10%
Cell Count
10%
Confidence Intervals
10%
Nephrectomy
10%
Cross Reactions
10%
HLA-A*02:01 antigen
9%
Ligands
9%
Therapeutics
9%
DNA Vaccines
8%
Membranes
8%
Active Immunotherapy
7%
Lung
7%
Genes
7%
Survival
6%
Immunological Synapses
6%